menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera S.A."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Isometheptene Mucate

    Menu

    Isometheptene Mucate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Takeda Pharmaceutical

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

                            Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...

                            Brand Name : Neosaldina

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 29, 2021

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Takeda Pharmaceutical

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD

                            Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Hypera Pharma

                            Deal Size : $825.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth